On March 29, 2023,
UBS
initiated coverage of Edwards Lifesciences with
a Neutral recommendation.
Analyst Price Forecast Suggests 9.47% Upside
As of March 29, 2023,
the average one-year price target for Edwards Lifesciences is $89.37.
The forecasts range from a low of $67.67 to a high of $105.00.
The average price target represents an increase of 9.47% from its latest reported closing price of $81.64.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Edwards Lifesciences
is $5,940MM, an increase of 10.36%.
The projected annual non-GAAP EPS
is $2.59.
What are Large Shareholders Doing?
Capital International Investors
holds 22,742K shares
representing 3.74% ownership of the company.
In it’s prior filing, the firm reported owning 22,697K shares, representing
an increase
of 0.20%.
The firm
decreased
its portfolio allocation in EW by 16.75% over the last quarter.
Alliancebernstein
holds 21,874K shares
representing 3.60% ownership of the company.
In it’s prior filing, the firm reported owning 17,161K shares, representing
an increase
of 21.55%.
The firm
increased
its portfolio allocation in EW by 6.98% over the last quarter.
Bank of New York Mellon
holds 19,210K shares
representing 3.16% ownership of the company.
In it’s prior filing, the firm reported owning 20,268K shares, representing
a decrease
of 5.51%.
The firm
decreased
its portfolio allocation in EW by 19.48% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 18,800K shares
representing 3.09% ownership of the company.
In it’s prior filing, the firm reported owning 18,489K shares, representing
an increase
of 1.66%.
The firm
decreased
its portfolio allocation in EW by 15.21% over the last quarter.
Wellington Management Group Llp
holds 15,272K shares
representing 2.51% ownership of the company.
In it’s prior filing, the firm reported owning 14,647K shares, representing
an increase
of 4.09%.
The firm
decreased
its portfolio allocation in EW by 11.37% over the last quarter.
What is the Fund Sentiment?
There are 2107 funds or institutions reporting positions in Edwards Lifesciences.
This is a decrease
of
428
owner(s) or 16.88% in the last quarter.
Average portfolio weight of all funds dedicated to EW is 0.30%,
a decrease
of 35.49%.
Total shares owned by institutions decreased
in the last three months by 0.36% to 587,954K shares.
The put/call ratio of EW is 0.68, indicating a
bullish
outlook.
Edwards Lifesciences Background Information
(This description is provided by the company.)
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
